Skip to main content
Premium Trial:

Request an Annual Quote

Thermo Fisher Buys Fermentas for $260M

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Thermo Fisher Scientific today announced it has signed a definitive agreement to buy reagents manufacturer Fermentas International for $260 million in cash.

The deal is expected to close in the third quarter and is not anticipated to have a material impact on Thermo Fisher's 2010 financial results, the company said in a statement.

Based in Burlington, Ontario, with principal operations in Vilnius, Lithuania, Fermentas employs about 500. In 2009, it posted revenues of about C$57 million ($54 million).

Among the products offered by Fermentas are reagents for nucleic acid and protein purification, restriction and modifying enzymes, molecular weight markers, and other life science research and diagnostic tools. It also offers various products for polymerase chain reaction, reverse transcription PCR, and quantitative PCR.

The acquisition of Fermentas will allow Thermo Fisher to better meet the demands of cellular and molecular biologists "for complete workflows that can accelerate their research and improve results," said Marc Casper, president and CEO of Thermo Fisher.

In March, Thermo Fisher completed its acquisition of Finnzymes, whose product portfolio includes proprietary DNA polymerases. Together, the Fermentas and Finnzymes acquisitions, along with the recent launch of Thermo Fisher's Solaris qPCR assay "enables us to strengthen our depth of capabilities in the high-growth PCR market," Casper added in the statement.

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people 65 and older or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.